How to write cold emails to investors – lessons from 30 VCs
Want to get your cold email to investors opened and read? Learn from the tips of some of the top VC investors.
Timo Särkkä
Fact: sending cold emails to investors can work.
The proof? Factmata raised a $500,000 investment from Mark Cuban through a cold email. Mapistry turned a cold outreach into a $2.5M funding round. Talkdesk, a company with a valuation of $3 billion, got initially funded through a well-crafted cold email.
But how to write a cold email to an investor? We took a deep dive to Twitter to find out what will get your email opened and read by VC investors.
Published: Feb 17, 2021
SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B.
The financing round was led by GreatPoint Ventures with support from existing investor ARTIS Ventures. New investors include Adjuvant Capital, Norwest Venture Partners, Anzu Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, and Olive Tree Capital. Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures, will join the Board of Di